Non-Small-Cell Lung Cancer
Conditions
Interventions
nab-paclitaxel 80mg/m2, day 1,8,15 cisplatin 60mg/m2 day 1 every 4 weeks Level 1
nab-paclitaxel 80mg/m2, day 1,8,15 cisplatin 75mg/m2 day 1 every 4 weeks Level 2
nab-paclitaxel 100mg/m2, day 1,8,15 cisplatin 75mg/m2 day 1 every 4 weeks
Sponsors
Hyogo Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically proven non-squamous non-small cell lung cancer 2)Non-small cell lung cancer with stage IIIB,stage IV (UICC-7) or recurrent disease after surgery 3)EGFR mutation negative, ALK rearrangement negative, other driver oncogenes negative 4)Age: 20- years old 5)ECOG PS 0-1 6)With measurable lesion 7)Adequate organ function 8)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)History of severe drug allergy 3)EGFR mutation positive, ALK rearrangement positive, other driver oncogenes positive 4)History of serious disease condition 5)Symptomatic brain metastasis 6)History of active double cancer 7)History of pregnancy or lactation 8)History of active psychological disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival, overall survival, toxicity | — |
Countries
Japan
Contacts
Public ContactYoshihiro Hattori
Hyogo Cancer Center Department of Thoracic Oncology
Outcome results
None listed